我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Climate change in healthcare: exploring the potential role of inhaler prescribing

Joachim Starup Hansen

Climate change has been described as the biggest global
health threat of the 21st century. As a result, governments
around the world are committing to legislative change in
order to reduce greenhouse gas emissions (GHGEs). The
healthcare sector makes a significant contribution to GHGEs
and in line with national legislation in the UK, the
NHS has recently committed to achieving net zero emissions
by 2050. The management of asthma and COPD
largely depends on the prescribing of medications that
are delivered through inhalers. In the UK, the use of
pressurised metered dose inhalers (pMDIs), which rely on
hydrofluorocarbon (HFC) propellants accounts for 3.5%
of the NHS’s total carbon footprint. In contrast, dry powder
inhalers (DPIs) have a much lower carbon footprint
due to the absence of a HFC propellant. Here we review
evidence of the impact of inhaler choices across four domains:
environmental impact, clinical effectiveness, cost
effectiveness and patient preferences. We find that as well
as a lower global warming potential, DPIs have additional
benefits over pMDIs in other domains and should be
considered first line where clinically appropriate.